TAK-279 for Plaque Psoriasis

Recruiting in Palo Alto (17 mi)

+218 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Takeda

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.

Research Team

Study Director

Principal Investigator

Takeda

Eligibility Criteria

This trial is for people who have had plaque psoriasis for at least 6 months and it's moderate to severe. They should be candidates for light therapy or systemic treatment but can't join if they've had other types of psoriasis, recent infections, or previous exposure to TAK-279.

Inclusion Criteria

You have been diagnosed with Plaque Psoriasis

Would you say that your plaque psoriasis affects more than 15 FULL palmprints' worth of your skin? (Add fractional palmprints as needed, e.g. 0.5 on your right arm, 1.5 on your left leg...)

Would you say that your plaque psoriasis affects more than 10 FULL palmprints' worth of your skin?

See 3 more

Exclusion Criteria

You have been diagnosed with Pustular Psoriasis

I have a type of psoriasis.

I have previously been treated with TAK-279 or a similar medication.

Treatment Details

Interventions

Apremilast (Other)
Placebo (Other)
TAK-279 (Other)

Trial OverviewThe study tests how well a new medication, TAK-279, works in reducing skin plaques compared to an existing drug called Apremilast and a placebo. Participants will randomly receive one of these treatments over the course of up to 69 weeks.

Participant Groups

3Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: TAK-279Experimental Treatment1 Intervention

Group II: ApremilastActive Control1 Intervention

Group III: PlaceboPlacebo Group1 Intervention

Apremilast is already approved in Canada, Japan for the following indications: